14th U.S. AI patent awarded complementing a comprehensive portfolio of AI-related intellectual property An ecosystem built around the...
Clinical team at Stanford Health Care achieved the CellTolerance 100-case milestone with the Cellvizio® platform in less than 6 months The...
Bridge financing through the issuance of convertible bonds to Vester Finance and European investors for €1.8m Immediate receipt of the entire...
Structuring of financing in progress to secure the safeguard period and support long-term development plan Authorization to implement the classes...
All the resolutions proposed by the Board of Directors were adopted Paris and Boston, June 5, 2025 - 5:45 p.m. CEST - Mauna Kea...
Cellvizio® technology combined with AI outperforms human experts in pancreatic cyst risk stratification, a major breakthrough for patient...
Ongoing Strategic Negotiations Towards a Licensing Agreement Strong Momentum for CellTolerance: Over 1,500 Procedures Completed, New Centers of...
Paris and Boston, May 20, 2025 - 5:45 p.m. CEST - Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary...
Over 75 physicians attended educational presentations about the breakthrough impact of needle-based Confocal Laser Endomicroscopy and AI on...
Paris and Boston, April 30, 2025 – 9:15 p.m. CEST – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary...
Pancreatic cyst abstracts build on endorsement of Cellvizio® by Europe’s leading endoscopy society, ESGE, as a key tool for improving pancreatic...
Commercial activities remain strong, including CellTolerance® launch Recently approved safeguard proceeding yielding productive creditor and...
